Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Keros Therapeutics Inc.
Headquarters: Lexington, MA, United States of America
Website: http://www.kerostx.com
Year Founded: 2015
Status: Public
Industry Sector: HealthTechnology
CEO: Jasbir S. Seehra, PhD
Number Of Employees: 169
Enterprise Value: $51,568,031
PE Ratio: -2.29
Exchange/Ticker 1: NASDAQ:KROS
Exchange/Ticker 2: N/A
Latest Market Cap: $465,246,080
BioCentury | Dec 18, 2024
Product Development
Merck, iTeos dropping assets, Viridian data — BioCentury’s Clinical Report
Plus: Readouts from Sanofi-Teva, Bicycle and more
BioCentury | Dec 10, 2024
Deals
Frustrated by IRA, Relay out-licenses ‘NDA-ready’ program to Elevar
Also in BioCentury’s Deals Report, a trio of biotech deals by GSK, and more
BioCentury | Jan 5, 2024
Finance
Catalysts drive follow-ons for Dyne, Longboard, Voyager in first week of 2024
Seven NASDAQ-listed biotechs together raise more than $1.6B in year’s first days, with Arrowhead drawing the largest amount
BioCentury | Feb 1, 2022
Management Tracks
Senti Bio, Sangamo alum Lee joins Lyell as CSO
Plus Leaming and Posner retire from Biogen’s board, Bourdon moves to Leo, and updates from Keros, NeoTX and more
BioCentury | Dec 15, 2021
Product Development
Dec. 14 Quick Takes: BeiGene deals with Nanjing for anti-LAG3 mAb
Plus: Pfizer confirms Paxlovid’s efficacy and updates from AnHeart, Generation and more
BioCentury | Aug 4, 2021
Management Tracks
Qian joins LianBio as general manager of China
Hoffman out as Zymergen CEO, plus updates from Scholar Rock, Ironwood, Keros, Madrigal and more
BioCentury | May 15, 2020
Finance
As biotech IPO pace quickens, ADC Therapeutics garners largest postmoney valuation of the year
Swiss cancer company’s debut is the latest sign of a robust market for fresh paper
Items per page:
1 - 10 of 18